Glong Hui, April 29, "Science and Technology Innovation Board Daily" on the 29th, Frontier Biology announced that the total amount of funds to be raised in the proposed offering does not exceed 300 million yuan and does not exceed 20% of the net assets at the end of the most recent year; after deducting the relevant issuance costs, the net funds raised will all be used for the medium-term analysis phase of the FB2001 R & D project. The fund-raising investment projects include phase I clinical trials in the research and development phase of COVID-19 's small molecule original drug FB2001, global phase II/III clinical trials (up to the mid-term analysis phase), and quality and process research.
前沿生物：拟定增募资用于新冠药FB2001研发项目
Frontier biology: plan to raise more funds for the new crown drug FB2001 research and development project
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.